NEW YORK (GenomeWeb News) – Cenix BioScience said today it will work with the drug developer AstraZeneca in a tailored RNAi research collaboration aimed at advancing oncology drug targets.
 
Under the agreement, Cenix will combine its RNAi-based gene silencing technology with phenotypic analyses in cultured human cells. The research program will initially involve a high-throughput RNAi screen using an assay that the companies will design together to find and validate novel targets for cancer treatments.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.